menu
    • menu
    [{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR 1","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Savolitinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"HMPL-453","moa":"FGFR1","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Savolitinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchison China MediTech \/ Hutchison China MediTech Limited","highestDevelopmentStatusID":"1","companyTruncated":"Hutchison China MediTech \/ Hutchison China MediTech Limited"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"HMPL-306","moa":"Isocitrate dehydrogenase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Fruquintinib","moa":"VEGFR","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison China MediTech \/ Eli Lilly"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fruquintinib","moa":"VEGFR","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"HMPL-689","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"capsule","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"VEGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Hutchison China MediTech","amount2":0.23000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Hutchison China MediTech \/ Inmagene","highestDevelopmentStatusID":"4","companyTruncated":"Hutchison China MediTech \/ Inmagene"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Savolitinib","moa":"HGF receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hutchison China MediTech \/ Not Applicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Surufatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hutchison China MediTech \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Hutchison China MediTech

    Menu

    Hutchison China MediTech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Savolitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC

                            Details : final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presented at the upcoming virtual 2020 World Conference on Lung Cancer (WCLC 2020).

                            Brand Name : HMPL-504

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 14, 2021

                            Lead Product(s) : Savolitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Inmagene Biopharmaceuticals

                            Deal Size : $230.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates ...

                            Details : Chi-Med grants Inmagene exclusive options to four drug candidates solely for the treatment of immunological diseases. Upon exercise of the option, Inmagene will have the right to further develop, manufacture and commercialize that specific drug candidate...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 11, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Inmagene Biopharmaceuticals

                            Deal Size : $230.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumo...

                            Details : The NMPA approval of Sulanda® was based on results from the SANET-ep study. The Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS in all subgroups of non-pancreatic NET patients with an acceptab...

                            Brand Name : Sulanda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 30, 2020

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroend...

                            Details : The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio.

                            Brand Name : HMPL-012

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 28, 2020

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amdizalisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting

                            Details : Abstract titled 'Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphoma" will be presented at the conference.

                            Brand Name : HMPL-689

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 05, 2020

                            Lead Product(s) : Amdizalisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chi-Med Highlights Surufatinib Phase III Results in Neuroendocrine Tumors at ESMO 2020 and Publications in The...

                            Details : Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”).

                            Brand Name : HMPL-012

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 20, 2020

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors

                            Details : The NDA is supported by data from the successful SANET-p study, a Phase III pivotal study of surufatinib in advanced neuroendocrine tumors – pancreatic patients in China for whom there is no effective therapy.

                            Brand Name : HMPL-012

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 17, 2020

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fruquintinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chi-Med Initiates FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer

                            Details : FRESCO-2 is a randomized, double-blind, placebo-controlled, multicenter trial being conducted in patients with metastatic CRC. The primary endpoint of the study is overall survival. This large phase III trial will be enrolled in approximately 130 sites i...

                            Brand Name : Elunate

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 04, 2020

                            Lead Product(s) : Fruquintinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020

                            Details : New and updated analyses on the studies of surufatinib and fruquintinib will be presented at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020.

                            Brand Name : HMPL-012

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 24, 2020

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hutchison China MediTech

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Chi-Med Plans to Submit Marketing Authorization Application for Surufatinib Following Scientific Advice from E...

                            Details : Application is based on the scientific advice which the company got from the European Medicines Agency’s Committee for Medicinal Products for Human Use for surufatinib for the treatment of patients with advanced neuroendocrine tumors.

                            Brand Name : HMPL-012

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 10, 2020

                            Lead Product(s) : Surufatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth